Midbrain organoids for in vitro
OrganoTherapeutics is a spin-off project from the University of Luxembourg. OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen for novel compounds which can be therapeutic for different patient sub-groups.
Proprietary 3D models derived from healthy individual and PD patient material
In the minibrains => identification of cellular defects which are missed in conventional methods. The therapeutic potential of compounds can be identified
The screening platform allows fully automated image and data analyses using artificial intelligence approaches
OT has access to unique libraries of chemically defined molecules (LDC) and natural molecules extracted from marine and floral organisms from Australia (Griffith University)
Javier Jarazo, PHD
Expert in stem cell models, phenotyping screening, and computational data analysis.
JENS SCHWAMBORN, PHD
Professor at the University of Luxembourg. Neuroscientist expert in stem cell research and Parkinson’s disease research.
Consultant; Previously at Luxembourgish Ministry of the Economy; Development of the Luxembourg strategy for biotech and personalized medicine.
MANUEL GAVIRIA, MD/PHD
Experienced entrepreneur. Serves as independent expert for the European Commission.
PAUL LINGOR MD, PROF.,
Medical doctor and clinical researcher at University Clinic Munich. Expert for Parkinson’s disease.
BERT KLEBL, PHD
Managing director and CSO at Lead Discovery Center. Expert for Drug Discovery and out-licensing.
LUIS PEREIRA DE ALMEIDA, PHD, PROF.,
Professor in Neuroscience and Pharmacy at University of Coimbra. Focus on Neurodegenerative diseases.